REVIEW
|
doi:10.20944/preprints202112.0282.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Acalabrutinib; Bruton’s tyrosine kinase; BTK; CLL; Covalent inhibitors; COVID-19; Ibrutinib; Non-covalent inhibitors; Fenebrutinib; MK1026; Pirtobrutinib; Spebrutinib; Tirabrutinib; Zanubrutinib
Online: 16 December 2021 (16:13:54 CET)
REVIEW
|
doi:10.20944/preprints202407.1534.v1
Subject:
Hematology,
Medicine And Pharmacology
Keywords:
lymphoma; B‐cell; hematologic neoplasms; bruton tyrosine kinase; protein kinase inhibitors; drug resistance; neoplasm; ibrutinib; pirtobrutinib; molecular targeted therapy; chronic lymphocytic leukemia; hematopoietic stem cell transplantation; covalent inhibitors; protein degradation
Online: 18 July 2024 (17:24:05 CEST)